A
Anaconda BioMed
Advanced catheters for safer mechanical thrombectomy in stroke
About Anaconda BioMed
Anaconda BioMed is a Barcelona medical-device company developing next-generation catheters for mechanical thrombectomy in ischemic stroke. Co-founded by Dr. Marc Ribo and Dr. Ofir Arad, its ANA Funnel Catheter and related ANCD Advanced Thrombectomy System combine covered-funnel and clot-mobilizer approaches intended to improve clot capture while reducing distal emboli and fragmentation versus conventional stentriever and aspiration techniques alone. The company is running the ATHENA pivotal IDE randomized study (about 327 subjects) to support U.S. regulatory progress alongside European commercialization ambitions. In September 2026 Anaconda secured a $56 million (about €49–50 million) equity financing led by Omega Funds, with new capital from FOCO/COFIDES and continued participation from Asabys, Ysios Capital and CDTI, to complete ATHENA, advance the catheter portfolio and pursue global approvals. Sources: GlobeNewswire / BioSpace 23 Sep 2026; Expansión.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Sant Cugat del Vallès, Spain
- Employees
- 44
- Open positions
- None listed
- Dealroom signal
- 80.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Cardiology and cardiovascular, Catheters, Intravenous, Spinout, Hospital, Headstart (EIT Health), Headstart 2018 (EIT Health), EIT Health
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jan 2025 | $3.7M | $111M | CDTI · Asabys Partners · Ysios Capital | ↗ |
| DEBT✓Debt | Oct 2021 | $11M | — | European Investment Bank | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Anaconda BioMed is 1.9K monthly website visits, up 35.7% over the last three months. Anaconda BioMed's team grew 2.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innogest Capital
Series A4 investors entered at this stage
Ysios Capital
Omega Funds
Sabadell Venture Capital
Asabys Partners
Series B and later2 investors entered at this stage
European Investment Bank
CDTI
Other known investors7 additional known investors
EIT Health
Vall d'Hebron Research Institute
Vall d'Hebron University Hospital
CDTI Innvierte
Claudio Rumazza
Sabadell Venture Debt- UFUri Fligil
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anaconda BioMed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anaconda BioMed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.